<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03713190</url>
  </required_header>
  <id_info>
    <org_study_id>EMPA-1</org_study_id>
    <nct_id>NCT03713190</nct_id>
  </id_info>
  <brief_title>Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).</brief_title>
  <official_title>A Phase II,Randomized,Cross-over,Double-blind, Placebo- Controlled,Single Center Study of the Effect of Empagliflozin a SGLT-2 Inhibitor,on Endogenous Glucose Production and Plasma Glucagon Levels in Patients With ESRD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pisa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pisa</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study of the effects of empagliflozin, a SGLT-2 inhibitor, on endogenous glucose production&#xD;
      and plasma glucagon levels in patients with end-stage renal disease (ESRD)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The impact of SGLT-2 inhibition on endogenous glucose production and plasma glucagon levels&#xD;
      will be compared measured in patients with ESRD.The secondary endpoints are the mean&#xD;
      difference in plasma glucose, insulin, c-peptide, FFA,GH, epinephrine, norepinephrine,&#xD;
      cortisol and blood pressure during the last hour of the experiment between empagliflozin&#xD;
      versus placebo administration in patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 10, 2018</start_date>
  <completion_date type="Actual">March 15, 2020</completion_date>
  <primary_completion_date type="Actual">February 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in plasma Glucose level</measure>
    <time_frame>2 hours</time_frame>
    <description>Because of their mechanism of action, SGLT-2 inhibitor efficacy to reduce plasma glucose level is highly dependent upon renal function. With GFR decreasing, glucose tubular load will decrease and less glucose will be reabsorbed because of SGLT2-inhibition.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SGLT-2 inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A substance without specific pharmacology principles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>Sodium-glucose co-transporter 2 (SGLT2), a low-affinity, high-capacity member of an increasingly numerous family of co-transporters, is highly expressed in the proximal renal tubule, and account for the majority of the reabsorption of filtered glucose.</description>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A substance without specific pharmacology principles</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females&#xD;
&#xD;
          2. Age = 30-70 years&#xD;
&#xD;
          3. BMI&amp;lt; 40 Kg/m 2 and stable weight (Â± 3 lbs) over the preceding three months&#xD;
&#xD;
          4. Normal Glucose Tolerance (HbA1c &amp;gt; 4.5 % and &amp;lt; 5.7%) or Type 2 diabetes (HbA1c&#xD;
             &amp;gt;5.7 % and &amp;lt;10.0%)&#xD;
&#xD;
          5. End Stage Renal Disease (GFR &amp;lt;15 ml/min/1.73 m 2 or hemodialysis)&#xD;
&#xD;
          6. Subjects are capable of giving informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prednisone treatment&#xD;
&#xD;
          2. Beta blocker or any medication that affects sympathetic/parasympathetic activity&#xD;
&#xD;
          3. Known Empagliflozin Excipient Hypersensitivity&#xD;
&#xD;
          4. Liver function enzymes higher more than two times the upper limit&#xD;
&#xD;
          5. Ongoing urinary tract infection&#xD;
&#xD;
          6. history of cancer of any type;&#xD;
&#xD;
          7. cerebrovascular or symptomatic peripheral vascular disease;&#xD;
&#xD;
          8. heart disease class III or IV NYHA;&#xD;
&#xD;
          9. Type 1 Diabetes&#xD;
&#xD;
         10. drug or alcohol abuse;&#xD;
&#xD;
         11. life expectancy &amp;lt;3 yrs&#xD;
&#xD;
         12. blood pressure &amp;gt;150/100 mmHg&#xD;
&#xD;
         13. Donation of blood to a blood bank, blood transfusion, or participation in a clinical&#xD;
             study requiring withdrawal of &amp;gt; 400 mL of blood during the 8 weeks prior to the&#xD;
             enrollment visit and at least 8 weeks thereafter&#xD;
&#xD;
         14. Women of child bearing potential who are unwilling or unable to use an acceptable&#xD;
             method to avoid pregnancy for the entire study (estrogen and/or progesterone&#xD;
             treatment)&#xD;
&#xD;
         15. Patient with a history or current evidence of any condition, therapy, laboratory&#xD;
             abnormality, or other circumstance which, in the opinion of the investigator or&#xD;
             coordinator, might pose an unacceptable risk to the patient or interfere with trial&#xD;
             procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Del prato</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pisa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Endocrinology and Metabolism, University of Pisa</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 18, 2018</study_first_submitted>
  <study_first_submitted_qc>October 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2018</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pisa</investigator_affiliation>
    <investigator_full_name>Prof. Stefano Del Prato</investigator_full_name>
    <investigator_title>Clinical Resercher</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

